FDA panel to review BrainStorm's NurOwn therapy for ALS

BrainStorm Cell Therapeutics (NASDAQ:BCLI) said that a US Food and Drug Administration advisory committee is set to review its biologics license application on Sept. 27 for its stem cell therapy NurOwn for the treatment of amyotrophic lateral sclerosis, or ALS.

The FDA has an action date of Dec. 8 to make a decision on whether to approve the product for ALS, according to the company.

More on BrainStorm:

Brainstorm Cell COO Setboun to leave company - filing

Brainstorm Cell Therapeutics Inc. SEC Filing - Quarterly Report (10-Q) May 15, 2023

Brainstorm granted FDA AdCom meeting for ALS therapy